DRI Returns with Second Pharmaceutical ABS

The deal, called Series 2012-2, is the second deal for DRI Capital this year, Moody's said. The rating agency rated both the earlier March transaction and the issuer’s latest offering.

The full article is available to Asset Securitization Report subscribers only

Free Trial
For immediate access, sign-up for a risk-free trial.

Already a print subscriber? As a print subscriber, you are entitled to online access. Please click here to activate your account.